Therefore, as enthusiasm for the preclinical development of novel MDM4/MDM2 inhibitors builds (reviewed in [3]), we propose that these future agents may show utility in combination with hormonal therapies for the treatment of MDM4/MDM2-driven breast cancers. This evidence concerns the gene MDM4 and breast carcinoma.